NewAmsterdam Pharma N.V.

NASDAQ: NAMS · Real-Time Price · USD
18.86
-1.38 (-6.82%)
At close: May 06, 2025, 3:59 PM
18.51
-1.86%
Pre-market: May 07, 2025, 04:58 AM EDT
-6.82%
Bid 14.34
Market Cap 2.12B
Revenue (ttm) 45.31M
Net Income (ttm) -232.13M
EPS (ttm) -2.56
PE Ratio (ttm) -7.37
Forward PE -11.65
Analyst Buy
Ask 23.98
Volume 1,079,177
Avg. Volume (20D) 976,960
Open 20.06
Previous Close 20.24
Day's Range 18.53 - 20.06
52-Week Range 14.06 - 27.29
Beta 0.01

About NAMS

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein ...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 9, 2021
Employees 68
Stock Exchange NASDAQ
Ticker Symbol NAMS
Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for NAMS stock is "Buy." The 12-month stock price forecast is $42, which is an increase of 122.69% from the latest price.

Stock Forecasts
2 months ago
+6.09%
NewAmsterdam Pharma shares are trading higher afte... Unlock content with Pro Subscription
2 months ago
+10.23%
NewAmsterdam Pharma shares are trading higher after the company reported better-than-expected FY24 sales results.